Amgen expands trial of Cytokinetics heart failure drug San Francisco Business Times (blog) The goal of the trial is to study omecamtiv mecarbil's safety, tolerability and pharmacokinetics — or how the body reacts to the drug — in patients with heart failure and left ventricular systolic dysfunction. Patients in the 20-week trial over about ... Cytokinetics Announces the Opening to Enrollment of the Expansion of COSMIC ... |
